Today a company called Decision Resources issued a report that identifies systemic lupus erythematosus (SLE, "lupus") as a growth market.
How macabre. The bad news is you have lupus. The good news is that the medical-pharmaceutical complex has found your cohort to be significant enough that they can afford to care.
Decision Resources, who bills itself as "one of the world's leading research and advisory firms for pharmaceutical and healthcare issues," says in a press release that it projects the market for SLE medicines to reach $1.4 billion in 2016. That's up from $325 last year so, hopefully, this growth will excite the pharmaceutical companies into finding more treatments for lupus.
Of course it is the "high-priced branded" medicines that, according to Decision Resources, will "drive the systemic lupus erythematosus drug market to quadruple" at up to 24% annual growth rates. But expensive medicine that works is better than no medicine at all.
Unfortunately for the pharmaceutical guys, a few of their high-end medicines will be going generic around 2011 and that's going to cause the hyper-growth to taper off to a meer 9% or so. Bummer, dude.
The good news: there's a market for lupus drugs. (We knew that, didn't we?)
The bad news: Shakespeare needs to rewrite Shylock into a different line of business.